Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
Nicola Clementi, Elena Criscuolo, Roberta Antonia Diotti, Roberto Ferrarese, Matteo Castelli, Lorenzo Dagna, Roberto Burioni, Massimo Clementi, Nicasio Mancini
Frontiers in Microbiology, doi:10.3389/fmicb.2020.01704
While the SARS-CoV-2 pandemic is heavily hitting the world, it is of extreme importance that significant in vitro observations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 and Caco-2 cells. This suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.
ETHICS STATEMENT The study involving human participants was reviewed and approved by Ospedale San Raffaele IRB in the COVID-19 Biobanking project. The patient from whose samples the virus was isolated provided written informed consent.
AUTHOR'S NOTE This manuscript has been released as a pre-print at bioRxiv preprint. doi: 10.1101/2020.03.29.014407, Hu et al. (2020) .
AUTHOR CONTRIBUTIONS NC and NM conceived the study. EC, RD, and RF performed the experiments. NC, NM, EC, MCa, and MCl analyzed the data. NC, NM, EC, and RD wrote the manuscript. NC, NM, LD, RB, and MCl revised the manuscript. All authors contributed to the article and approved the submitted version. coronavirus (2019-nCoV) in vitro. Cell Res. 30, 1-3. doi: 10.1038/s41422-020-0282-0 Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., et al. (2020) . In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. doi: 10.1093/cid/ciaa237. [Epub ahead of print]. Zhou, D., Dai, S.-M., and Tong, Q. (2020). COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J. Antimicrob. Chemother. 63, 457-454. doi: 10.1093/jac/ dkaa114 Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest...
References
Chatre, Roubille, Vernhet, Jorgensen, Pers, Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature, Drug Saf,
doi:10.1007/s40264-018-0689-4Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends,
doi:10.5582/bst.2020.01047Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.105949Hirotsu, Mochizuki, Omata, Double-quencher probes improved the detection sensitivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by one-step RT-PCR, medRxiv,
doi:10.1101/2020.03.17.20037903Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov,
doi:10.1038/s41421-020-0156-0Mehra, Desai, Kuy, Henry, Patel, Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMc2021225Mehra, Desai, Ruschitzka, Patel, RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet,
doi:10.1016/S0140-6736(20)31180-6Tu, Chien, Yarmishyn, Lin, Luo et al., A review of SARS-CoV-2 and the ongoing clinical trials, IJMS,
doi:10.3390/ijms21072657Vincent, Bergeron, Benjannet, Erickson, Rollin et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol. J,
doi:10.1186/1743-422X-2-69Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel
DOI record:
{
"DOI": "10.3389/fmicb.2020.01704",
"ISSN": [
"1664-302X"
],
"URL": "http://dx.doi.org/10.3389/fmicb.2020.01704",
"alternative-id": [
"10.3389/fmicb.2020.01704"
],
"author": [
{
"affiliation": [],
"family": "Clementi",
"given": "Nicola",
"sequence": "first"
},
{
"affiliation": [],
"family": "Criscuolo",
"given": "Elena",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Diotti",
"given": "Roberta Antonia",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ferrarese",
"given": "Roberto",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Castelli",
"given": "Matteo",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Dagna",
"given": "Lorenzo",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Burioni",
"given": "Roberto",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Clementi",
"given": "Massimo",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Mancini",
"given": "Nicasio",
"sequence": "additional"
}
],
"container-title": "Frontiers in Microbiology",
"container-title-short": "Front. Microbiol.",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"frontiersin.org"
]
},
"created": {
"date-parts": [
[
2020,
7,
10
]
],
"date-time": "2020-07-10T05:16:55Z",
"timestamp": 1594358215000
},
"deposited": {
"date-parts": [
[
2020,
7,
10
]
],
"date-time": "2020-07-10T05:16:56Z",
"timestamp": 1594358216000
},
"indexed": {
"date-parts": [
[
2024,
5,
14
]
],
"date-time": "2024-05-14T18:33:52Z",
"timestamp": 1715711632477
},
"is-referenced-by-count": 15,
"issued": {
"date-parts": [
[
2020,
7,
10
]
]
},
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
7,
10
]
],
"date-time": "2020-07-10T00:00:00Z",
"timestamp": 1594339200000
}
}
],
"link": [
{
"URL": "https://www.frontiersin.org/article/10.3389/fmicb.2020.01704/full",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1965",
"original-title": [],
"prefix": "10.3389",
"published": {
"date-parts": [
[
2020,
7,
10
]
]
},
"published-online": {
"date-parts": [
[
2020,
7,
10
]
]
},
"publisher": "Frontiers Media SA",
"reference": [
{
"DOI": "10.1007/s40264-018-0689-4",
"article-title": "Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature",
"author": "Chatre",
"doi-asserted-by": "publisher",
"first-page": "919",
"journal-title": "Drug Saf.",
"key": "B1",
"volume": "41",
"year": "2018"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105932",
"article-title": "Chloroquine and hydroxychloroquine as available weapons to fight COVID-19",
"author": "Colson",
"doi-asserted-by": "publisher",
"first-page": "105932",
"journal-title": "Int. J. Antimicrob. Agents",
"key": "B2",
"volume": "55",
"year": "2020"
},
{
"DOI": "10.1016/S1473-3099(20)30120-1",
"article-title": "An interactive web-based dashboard to track COVID-19 in real time",
"author": "Dong",
"doi-asserted-by": "publisher",
"first-page": "533",
"journal-title": "Lancet Infect Dis",
"key": "B3",
"volume": "20",
"year": "2020"
},
{
"DOI": "10.5582/bst.2020.01047",
"article-title": "Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
"author": "Gao",
"doi-asserted-by": "publisher",
"first-page": "72",
"journal-title": "Biosci. Trends",
"key": "B4",
"volume": "14",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial",
"author": "Gautret",
"doi-asserted-by": "publisher",
"journal-title": "Int. J. Antimicrob. Agents",
"key": "B5",
"year": "2020"
},
{
"DOI": "10.1101/2020.03.17.20037903",
"article-title": "Double-quencher probes improved the detection sensitivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by one-step RT-PCR",
"author": "Hirotsu",
"doi-asserted-by": "publisher",
"journal-title": "medRxiv",
"key": "B6",
"year": "2020"
},
{
"DOI": "10.1038/s41565-020-0674-9",
"article-title": "Insights from nanomedicine into chloroquine efficacy against COVID-19",
"author": "Hu",
"doi-asserted-by": "publisher",
"first-page": "247",
"journal-title": "Nat. Nanotechnol",
"key": "B7",
"volume": "15",
"year": "2020"
},
{
"DOI": "10.1038/s41421-020-0156-0",
"article-title": "Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro",
"author": "Liu",
"doi-asserted-by": "publisher",
"first-page": "16",
"journal-title": "Cell Discov",
"key": "B8",
"volume": "6",
"year": "2020"
},
{
"DOI": "10.1056/NEJMc2021225",
"article-title": "Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19",
"author": "Mehra",
"doi-asserted-by": "publisher",
"first-page": "2582",
"journal-title": "N. Engl. J. Med",
"key": "B9",
"volume": "382",
"year": ""
},
{
"DOI": "10.1016/S0140-6736(20)31180-6",
"article-title": "RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis",
"author": "Mehra",
"doi-asserted-by": "publisher",
"first-page": "1820",
"journal-title": "Lancet",
"key": "B10",
"volume": "395",
"year": ""
},
{
"DOI": "10.1126/science.368.6495.1041",
"article-title": "The pandemic's first major research scandal erupts",
"doi-asserted-by": "publisher",
"first-page": "1",
"journal-title": "Science",
"key": "B11",
"volume": "386",
"year": "2020"
},
{
"DOI": "10.3390/ijms21072657",
"article-title": "A review of SARS-CoV-2 and the ongoing clinical trials",
"author": "Tu",
"doi-asserted-by": "publisher",
"first-page": "2657",
"journal-title": "IJMS",
"key": "B12",
"volume": "21",
"year": "2020"
},
{
"DOI": "10.1186/1743-422X-2-69",
"article-title": "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread",
"author": "Vincent",
"doi-asserted-by": "publisher",
"first-page": "69",
"journal-title": "Virol. J.",
"key": "B13",
"volume": "2",
"year": "2005"
},
{
"DOI": "10.1038/s41422-020-0282-0",
"article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
"author": "Wang",
"doi-asserted-by": "publisher",
"first-page": "1",
"journal-title": "Cell Res",
"key": "B14",
"volume": "30",
"year": "2020"
},
{
"DOI": "10.1093/cid/ciaa237",
"article-title": "In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)",
"author": "Yao",
"doi-asserted-by": "publisher",
"journal-title": "Clin. Infect. Dis",
"key": "B15",
"year": "2020"
},
{
"DOI": "10.1093/jac/dkaa114",
"article-title": "COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression",
"author": "Zhou",
"doi-asserted-by": "publisher",
"first-page": "457",
"journal-title": "J. Antimicrob. Chemother.",
"key": "B16",
"volume": "63",
"year": "2020"
}
],
"reference-count": 16,
"references-count": 16,
"relation": {
"has-preprint": [
{
"asserted-by": "object",
"id": "10.1101/2020.03.29.014407",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "https://www.frontiersin.org/article/10.3389/fmicb.2020.01704/full"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.3389/crossmark-policy",
"volume": "11"
}
